Genelux Corporation to Participate in Upcoming Conferences
Rhea-AI Summary
Genelux (NASDAQ: GNLX) will participate in two investor conferences in late February and early March 2026. Management will deliver a virtual fireside chat on Feb 25, 2026 at 11:20 a.m. ET and a live presentation on Mar 2, 2026 at 2:30 p.m. ET in Boston.
Live webcasts and archived replays will be available on the company’s Events & Presentations investor relations webpage.
Positive
- None.
Negative
- None.
News Market Reaction – GNLX
In the Feb 18 session, GNLX gained 2.34%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Investor conference | Neutral | -5.4% | Announcement of a virtual fireside chat with Titan Partners. |
| Jan 08 | Equity offering priced | Negative | -19.8% | Pricing of $20M underwritten common stock offering at $3.00. |
| Jan 07 | Equity offering proposed | Negative | +0.0% | Announcement of proposed underwritten public stock offering under shelf. |
| Jan 05 | Clinical data update | Positive | -23.5% | Interim Olvi-Vec lung cancer data with notable response and control rates. |
| Jan 02 | Management change | Positive | +4.4% | Appointment of Jason Litten, M.D., as Chief Medical Officer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows negative reactions to clinical data and equity offerings, while a management hire drew a modestly positive response.
Over the past few months, Genelux has combined clinical updates, financings, and corporate changes. A January conference-related event on Jan 19, 2026 was followed by a -5.36% move. Two January offerings, including a $20.0 million underwritten deal at $3.00, saw pressure, with one day down -19.76%. Encouraging lung cancer interim data on Jan 5, 2026 coincided with a -23.52% reaction, while the CMO appointment on Jan 2, 2026 drew a 4.36% gain. Today’s conference participation fits this pattern of active investor outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences.
- Oppenheimer Healthcare Life Sciences Conference: Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat on Wednesday, February 25, 2026, at 11:20 a.m. ET.
- TD Cowen 46th Annual Health Care Conference: Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, Chief Financial Officer, will participate in a presentation on Monday, March 2, 2026, at 2:30 p.m. ET in Boston, MA.
Live webcasts of the fireside chat and presentation can be found on the Events & Presentations section of the Company’s Investor Relations website at https://investors.genelux.com/news-events/events-presentations. Following the completion of the events, an archived replay of each webcast will be available on the Company’s Investor Relations website.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b/2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which Genelux has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
Investor Contact
Austin Murtagh
Precision AQ
austin.murtagh@precisionaq.com
Media Contact
Ashley Murphy
Precision AQ
ashley.murphy@precisionaq.com
Source: Genelux Corporation
